15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 19 firms covering Cytokinetics Inc, 18 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $84.00 to $140.00, a moderate spread. The average target of $104.63 sits 32% above the current $79.49. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 17 to 18 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.54 next quarter toward $-4.69 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS19 ratings
Moderate Buy
Strong Buy00%
Buy1895%
Hold15%
Sell00%
Strong Sell00%
Based on 19 analysts giving stock ratings to Cytokinetics Inc.
As of Jul, 18 of 19 firms rate CYTK a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
CYTK EPS & revenue forecast
EPS · NEXT QUARTER
$-1.54
Range $-1.90 – $-1.05 · 15 analysts · +0% YoY
Next period, 15 analysts expect Cytokinetics Inc to earn $-1.54 a share (range $-1.90 – $-1.05), versus $-1.54 a year earlier. Full-year consensus is $-6.31, growing to $-4.69 the year after.
REVENUE · NEXT QUARTER
$27.7M
Range $17.8M – $46.1M · 15 analysts · +1333% YoY
Revenue is expected to reach $27.7M (range $17.8M – $46.1M), +1332.6% year-over-year. Full-year consensus is $112.9M, rising to $393.4M next year.
Top analysts covering Cytokinetics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CYTK.
#1
Mayank Mamtani
B. Riley Securities · Rank #9
Buy
$108.00+35.9% to target
Overall win rate
53%
+ Follow
#2
JH
Jeffrey Hung
Morgan Stanley · Rank #12
Buy
$103.00+29.6% to target
Overall win rate
61%
+ Follow
#3
Jason Butler
JMP Securities · Rank #22
Buy
$96.00+20.8% to target
Overall win rate
57%
+ Follow
#4
Leonid Timashev
RBC Capital · Rank #69
Buy
$117.00+47.2% to target
Overall win rate
42%
+ Follow
#5
Serge Belanger
Needham · Rank #83
Buy
$102.00+28.3% to target
Overall win rate
48%
+ Follow
CYTK stock forecast FAQ
What is CYTK's average 12-month price target?+
The 16 analysts with a live target average $104.63 for Cytokinetics Inc over the next 12 months, ranging from a $140.00 high to a $84.00 low.
Is CYTK stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 19 analyst ratings, 18 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for CYTK?+
The Street-high target is $140.00 (HC Wainwright & Co.), and the Street-low is $84.00 (Leerink Partners). The average of all 16 active targets is $104.63.
How many Wall Street analysts cover CYTK?+
19 analysts have an active rating on Cytokinetics Inc, and 16 firms carry a live 12-month price target.
Who is the most accurate analyst covering CYTK?+
Among analysts who currently cover CYTK, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #9). Their current call is Buy with a $108.00 target.
What is Cytokinetics Inc's projected EPS for next quarter?+
The consensus estimate is $-1.54 per share (range $-1.90 – $-1.05) across 15 analysts. Full-year EPS is projected at $-6.31, rising to $-4.69 the following year.
How much revenue is Cytokinetics Inc expected to report next quarter?+
Consensus revenue is $27.7M (range $17.8M – $46.1M). Full-year revenue is projected at $112.9M, growing to $393.4M next year.
Have analysts been upgrading or downgrading CYTK lately?+
As of Jul, 18 of 19 firms rate CYTK a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CYTK calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
